Is Dogwood Therapeutics, Inc. (DWTX) a Buy, Sell, or Hold?
NASDAQ : DWTX
Dogwood Therapeutics, Inc.
$1.38 USD
$0.01 (0.73%)
- Volume
- 31.59K
- Average Volume
- 95.45K
- Market Capitalization
- $2.64M
- P/E Ratio
- -0.13
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $9.50
- Year Low
- $1.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.86
| Source | Headline |
|---|---|
|
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 globenewswire.com - 2026-06-30 08:45:00 |
|
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript seekingalpha.com - 2026-06-16 12:02:09 |
|
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package globenewswire.com - 2026-05-18 08:45:00 |
|
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - globenewswire.com - 2026-05-14 08:30:00 |
|
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. globenewswire.com - 2026-05-07 08:30:00 |
|
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net Sales - - Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 - ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor Therapeutics, LLC (“PRIDCor”), a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood's anti-viral candidates, IMC-1 and IMC-2. globenewswire.com - 2026-04-23 09:00:00 |
